Screener
Rigel Pharmaceuticals RIGL Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Contract revenues from collaborations | 3,895 | 9,783 |
| Total revenues | 58,818 | 53,333 |
| Costs and expenses: | ||
| Cost of product sales | 4,606 | 4,409 |
| Research and development | 11,676 | 8,436 |
| Selling, general and administrative | 30,651 | 27,715 |
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total cost of revenue?
- Rigel Pharmaceuticals (RIGL) reported total cost of revenue of $4.61M in Q1 2026.
- How has Rigel Pharmaceuticals's total cost of revenue changed year-over-year?
- Rigel Pharmaceuticals's total cost of revenue increased by 4.5% year-over-year, from $4.41M to $4.61M.
- What is the long-term trend for Rigel Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's total cost of revenue has grown at a 106.3% compound annual growth rate (CAGR), from $1.08M to $19.62M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Rigel Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude